CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: 2019-12-26

DOI: 10.1073/pnas.1910856117

Affiliations: 6

Authors: 12

Go to article
Institutions Share
ChemoCentryx, Inc., United States of America (USA) 0.33
Department of Pharmacology and Therapeutics, UF, United States of America (USA) 0.29
Edwin L. Steele Laboratories, MGH, United States of America (USA) 0.17
Department of Neuroscience, UF, United States of America (USA) 0.08
Preston A. Wells, Jr. Center for Brain Tumor Therapy, UF, United States of America (USA) 0.08
Lillian S. Wells Department of Neurosurgery, UF, United States of America (USA) 0.04

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER